Merck & Co., Inc: COVID-19 trials
The registry lists 11 COVID-19 studies with Merck & Co., Inc as lead sponsor. 1 are open to participants now and 8 have results posted.
Phase 1 4Phase 2 4Phase 3 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)RecruitingNCT06667700Phase 3
- Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)CompletedNCT05119855Phase 3Results posted
- Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)CompletedNCT04939428Phase 3Results posted
- Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)CompletedNCT04575597Phase 2/3Results posted
- Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)TerminatedNCT04575584Phase 2/3Results posted
- Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)TerminatedNCT04569786Phase 1Results posted
- Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19CompletedNCT04527471Phase 2Results posted
- A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)TerminatedNCT04498247Phase 1/2Results posted
- Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)CompletedNCT04317040Phase 3Results posted
- A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)CompletedNCT06816030Phase 1
- Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)WithdrawnNCT04425733Phase 1